Abstract
Atrial fibrillation is the most common clinically significant cardiac arrhythmia and is associated with markedly increased risks of cardiovascular diseases. Atrial fibrillation and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a blocker of the reninangiotensin system, may postpone or prevent development of atrial fibrillation and reduce thromboembolic complications. Awareness of the risk of developing atrial fibrillation in hypertensives may be of great importance and focus on prevention of atrial fibrillation development with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, atrial fibrillation, hypertension, renin-angiotensin system, cardiac arrhythmia, cardiovascular diseases, thromboembolic complications, Framingham Heart Study, systolic blood pressure, electrocardiogram, ANTIHYPERTEN-SIVE TREATMENT, RAS-blockade, cardiac hypertrophy, left ventricular hypertrophy, beta-blocker, valsartan, calcium channel blockers, (lisinopril), (doxazosin), (chlorthalidone), (losartan), (amlodipine), atenolol/amlodipine, telmisartan, ESH/ESC guidelines, anti-arrhythmic drugs, (ramipril), (irbesartan), myocardial infarction, diltiazem, Diuretics, hydrochlorothiazide, Alpha-Adrenoreceptor Blocker
Current Vascular Pharmacology
Title: A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention
Volume: 8 Issue: 6
Author(s): Tonje A. Aksnes and Sverre E. Kjeldsen
Affiliation:
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II type I receptor blockers, atrial fibrillation, hypertension, renin-angiotensin system, cardiac arrhythmia, cardiovascular diseases, thromboembolic complications, Framingham Heart Study, systolic blood pressure, electrocardiogram, ANTIHYPERTEN-SIVE TREATMENT, RAS-blockade, cardiac hypertrophy, left ventricular hypertrophy, beta-blocker, valsartan, calcium channel blockers, (lisinopril), (doxazosin), (chlorthalidone), (losartan), (amlodipine), atenolol/amlodipine, telmisartan, ESH/ESC guidelines, anti-arrhythmic drugs, (ramipril), (irbesartan), myocardial infarction, diltiazem, Diuretics, hydrochlorothiazide, Alpha-Adrenoreceptor Blocker
Abstract: Atrial fibrillation is the most common clinically significant cardiac arrhythmia and is associated with markedly increased risks of cardiovascular diseases. Atrial fibrillation and hypertension often coexist and are both responsible for considerable morbidity and mortality. Aggressive treatment of hypertension, especially with a blocker of the reninangiotensin system, may postpone or prevent development of atrial fibrillation and reduce thromboembolic complications. Awareness of the risk of developing atrial fibrillation in hypertensives may be of great importance and focus on prevention of atrial fibrillation development with optimal antihypertensive treatment may reduce morbidity, mortality and health care expenditures.
Export Options
About this article
Cite this article as:
A. Aksnes Tonje and E. Kjeldsen Sverre, A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563807
DOI https://dx.doi.org/10.2174/157016110793563807 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exercise in Youth with Type 1 Diabetes
Current Pediatric Reviews Air Pollution, Platelet Activation and Atherosclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design A Review on Genus Alseodaphne: Phytochemistry and Pharmacology
Mini-Reviews in Organic Chemistry Circulating Exosomes and Their Role in Stroke
Current Drug Targets Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy
Current Vascular Pharmacology Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Soy Isoflavones and Cardiovascular Disease Epidemiological, Clinical and -Omics Perspectives
Current Pharmaceutical Biotechnology Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials
Reviews on Recent Clinical Trials Three-Dimensional Ultrasound in Fetal Size and Growth Assessment
Current Medical Imaging The J-shaped Association Between Alcohol Consumption and Breast Cancer: A Case-Control Study
Current Nutrition & Food Science Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets EDITORIAL [Hot Topic: Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Ophthalmic Conditions (Guest Editor: Michael W. Stewart)]
Current Drug Therapy Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Role of Infrared Spectroscopy in Medicinal Plants Research in Pakistan
Current Bioactive Compounds Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin
Current Drug Safety